Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood - Archive ouverte HAL Access content directly
Journal Articles BMC Immunology Year : 2021

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

(1, 2) , (2) , (1, 3) , (1) , (2) , (1) , (3, 4) , (1, 3) , (1, 3) , (1, 3) , (5) , (1, 6) , (2, 1)
1
2
3
4
5
6

Abstract

Background: The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer. Materials and methods: Peripheral blood mononuclear cells were collected at baseline and 1 month after treatment from blood samples of 29 patients treated with cisplatin-based chemoradiotherapy for lung or head and neck cancer. Circulating anti-tumor Th1 response was assessed by the ELISpot assay using a mixture of human leucocyte antigen (HLA) class II restricted peptides derived from telomerase (TERT). Phenotyping of circulating immunosuppressive cells (Treg and MDSC) was performed by flow cytometry. Results: A significant increase of circulating Treg was observed in 60% of patients after CRT The mean rate of Treg was 3.1% versus 4.9% at baseline and after CRT respectively, p = 0.0015). However, there was a no significant increase of MDSC rate after CRT. In contrast, a decrease of tumor-specific Th1 response was documented in 7 out of 10 evaluated patients. We found high frequency of pre-existing tumor-specific Th1 response among patients with objective response after CRT compared to non-responders. Conclusion: Cisplatin-based CRT promotes expansion of Treg and decrease of circulating anti-tumor Th1 response in peripheral blood. The balance towards a sustained specific anti-tumor T-cell response appears to be associated with response to CRT.
Fichier principal
Vignette du fichier
s12865-021-00429-5.pdf (1.51 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03310682 , version 1 (30-07-2021)

Identifiers

Cite

Jihane Boustani, Elodie Lauret Marie Joseph, Etienne Martin, Salim Benhmida, Benoit Lecoester, et al.. Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunology, 2021, 22 (1), pp.38. ⟨10.1186/s12865-021-00429-5⟩. ⟨inserm-03310682⟩
66 View
28 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More